143 related articles for article (PubMed ID: 1260652)
21. BCNU with and without cyclophosphamide, vincristine, and prednisone (COP) and cycle-active therapy in non-Hodgkin's lymphoma.
Durant JR; Gams RA; Bartolucci AA; Dorfman RF
Cancer Treat Rep; 1977 Sep; 61(6):1085-96. PubMed ID: 332345
[TBL] [Abstract][Full Text] [Related]
22. Non-cross-resistant combinations in stage IV non-Hodgkin's lymphomas.
Bonadonna G; Monfardini S; Villa E
Cancer Treat Rep; 1977 Sep; 61(6):1117-23. PubMed ID: 71209
[TBL] [Abstract][Full Text] [Related]
23. The place of radiation therapy in the treatment of non-Hodgkin's lymphomas.
Hellman S; Chaffey JT; Rosenthal DS; Moloney WC; Canellos GP; Skarin AT
Cancer; 1977 Feb; 39(2 Suppl):843-51. PubMed ID: 65208
[TBL] [Abstract][Full Text] [Related]
24. Chemotherapy (cyclophosphamide, vincristine, and prednisone) versus radiotherapy (total body irradiation) for stage III-IV poorly differentiated lymphocytic lymphoma.
Johnson RE; Canellos GP; Young RC; Chabner BA; DeVita VT
Cancer Treat Rep; 1978 Mar; 62(3):321-5. PubMed ID: 580598
[TBL] [Abstract][Full Text] [Related]
25. Effects of Mega-COMLA (cyclophosphamide, cytarabine, vincristine, and methotrexate followed by leucovorin and prednisone) plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) in the treatment of lymphoid neoplasms with very poor prognosis.
Hainsworth JD; Wolff SN; Stein RS; Greer JP; Cousar JB; Greco FA
Cancer Treat Rep; 1986 Aug; 70(8):953-8. PubMed ID: 3015406
[TBL] [Abstract][Full Text] [Related]
26. Phase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients with stage III and IV low-grade malignant Non-Hodgkin's lymphoma.
Hagenbeek A; Eghbali H; Monfardini S; Vitolo U; Hoskin PJ; de Wolf-Peeters C; MacLennan K; Staab-Renner E; Kalmus J; Schott A; Teodorovic I; Negrouk A; van Glabbeke M; Marcus R
J Clin Oncol; 2006 Apr; 24(10):1590-6. PubMed ID: 16575010
[TBL] [Abstract][Full Text] [Related]
27. 1,3-bis(2-chloroethyl)-1-nitrosourea(BCNU), cyclophosphamide, vincristine- and prednisone-(BCOP). A new therapeutic regimen for diffuse histiocytic lymphoma.
Durant JR; Loeb V; Dorfman R; Chan YK
Cancer; 1975 Dec; 36(6):1936-44. PubMed ID: 1106833
[TBL] [Abstract][Full Text] [Related]
28. Effect of splenectomy on tolerance to combination chemotherapy in patients with lymphoma.
Ihde DC; DeVita VT; Canellos GP; Young RC
Blood; 1976 Feb; 47(2):211-22. PubMed ID: 1244920
[TBL] [Abstract][Full Text] [Related]
29. Bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP) combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma.
Schein PS; DeVita VT; Hubbard S; Chabner BA; Canellos GP; Berard C; Young RC
Ann Intern Med; 1976 Oct; 85(4):417-22. PubMed ID: 61732
[TBL] [Abstract][Full Text] [Related]
30. The treatment of advanced stage favorable histology non-Hodgkin's lymphoma: a preliminary report of a randomized trial comparing single agent chemotherapy, combination chemotherapy, and whole body irradiation.
Hoppe RT; Kushlan P; Kaplan HS; Rosenberg SA; Brown BW
Blood; 1981 Sep; 58(3):592-8. PubMed ID: 7259838
[TBL] [Abstract][Full Text] [Related]
31. Combination chemotherapy of advanced, diffuse, non-Hodgkin's lymphoma: results with cyclo-phosphamide, adriamycin, vincristine, prednisone, and bleomycin (CHOP-Bleo).
Case DC
J Maine Med Assoc; 1979 Sep; 70(9):348-50, 352, 368. PubMed ID: 92513
[No Abstract] [Full Text] [Related]
32. A clinicopathologic study in advanced non-Hodgkin's lymphomas treated with sequential non-cross-resistant regimens: comparison of the working formulation with the Rappaport and Kiel classifications.
Monfardini S; Rilke F; Valagussa P; Bajetta E; Canetta R; Buzzoni R; Giardini R; Viviani S
Eur J Cancer Clin Oncol; 1984 May; 20(5):609-17. PubMed ID: 6203753
[TBL] [Abstract][Full Text] [Related]
33. Combination chemotherapy followed by an immunotoxin (anti-B4-blocked ricin) in patients with indolent lymphoma: results of a phase II study.
Longo DL; Duffey PL; Gribben JG; Jaffe ES; Curti BD; Gause BL; Janik JE; Braman VM; Esseltine D; Wilson WH; Kaufman D; Wittes RE; Nadler LM; Urba WJ
Cancer J; 2000; 6(3):146-50. PubMed ID: 10882329
[TBL] [Abstract][Full Text] [Related]
34. Advances in chemotherapy for large cell lymphoma.
Coleman M; Gerstein G; Topilow A; Lebowicz J; Berhardt B; Chiarieri D; Silver RT; Pasmantier MW
Semin Hematol; 1987 Apr; 24(2 Suppl 1):8-20. PubMed ID: 2438781
[TBL] [Abstract][Full Text] [Related]
35. Rituximab for the first-line treatment of stage III/IV follicular non-Hodgkin's lymphoma.
Dundar Y; Bagust A; Hounsome J; McLeod C; Boland A; Davis H; Walley T; Dickson R
Health Technol Assess; 2009 Jun; 13 Suppl 1():23-8. PubMed ID: 19567210
[TBL] [Abstract][Full Text] [Related]
36. Non-Hodgkin's lymphoma in Manitoba, 1968-77: the impact of chemotherapy.
Deonarine L; Weinerman BH; MacDougall BK; Kemel S
Can Med Assoc J; 1982 Apr; 126(7):807-11. PubMed ID: 7042060
[TBL] [Abstract][Full Text] [Related]
37. Nodular mixed lymphoma: results of a randomized trial failing to confirm prolonged disease-free survival with COPP chemotherapy.
Glick JH; Barnes JM; Ezdinli EZ; Berard CW; Orlow EL; Bennett JM
Blood; 1981 Nov; 58(5):920-5. PubMed ID: 7028181
[TBL] [Abstract][Full Text] [Related]
38. Prospectively randomized clinical trial of three intensive chemotherapy regimens for the treatment of advanced unfavorable histology non-Hodgkin's lymphoma.
O'Connell MJ; Harrington DP; Earle JD; Johnson GJ; Glick JH; Carbone PP; Creech RH; Neiman RS; Mann RB; Silverstein MN
J Clin Oncol; 1987 Sep; 5(9):1329-39. PubMed ID: 2442322
[TBL] [Abstract][Full Text] [Related]
39. 5-year survey of methotrexate, cyclophosphamide (Endoxan), and vincristine (MEV) therapy for advanced non-Hodgkin's lymphomas.
Lauria F; Baccarani M; Fiacchini M; Frezza R; Gobbi M; Tura S
Cancer Treat Rep; 1978 Aug; 62(8):1193-7. PubMed ID: 688255
[TBL] [Abstract][Full Text] [Related]
40. Bleomycin, epidoxorubicin, cyclophosphamide, vincristine and prednisone (BACOP) in patients with follicular non-Hodgkin's lymphoma: results of a prospective, multicenter study of the Gruppo Italiano Per Lo Studio Dei Linfomi (GISL).
Lombardo M; Morabito F; Merli F; Molica S; Cavanna L; Sacchi S; Broglia C; Angrilli F; Ilariucci F; Stelitano C; Luisi D; Bertè R; Luminari S; Federico M; Brugiatelli M;
Leuk Lymphoma; 2002 Sep; 43(9):1795-801. PubMed ID: 12685834
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
